search
Back to results

Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)

Primary Purpose

Carotid Artery Disease

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
-PRECISE Nitinol Stent System (5F, 5.5F and 6F)
ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)
Sponsored by
Cordis Corporation
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carotid Artery Disease

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: The patient must be > 18 years of age. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as: one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms. To be entered into the study, the patient must have one or more of the following conditions: · congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30% open heart surgery within six weeks recent MI (>24 hours and <4 weeks) unstable angina (CCS class III/IV) synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization severe pulmonary disease to include any of the following: chronic oxygen therapy resting PO2 of 60 mmHg baseline hematocrit 50% FEV1 or DLCO 50% of normal. · contralateral carotid occlusion · contralateral laryngeal palsy · post-radiation treatment · previous CEA recurrent stenosis · high cervical ICA lesions · CCA lesions below the clavicle · severe tandem lesions abnormal stress test. 4. The qualifying ultrasound or angiogram was performed less than 30 days prior to study entry. · Stenosis >50%: PSV>130 cm/sec; EDV <135 cm/sec · Stenosis >80%: PSV>220 cm/sec; EDV <135 cm/sec · PSV ICA/PSV CCA ratio 4.0 5. The target vessel is in the native common or internal carotid artery. The arterial segment to be treated has a diameter between 4 mm and 9 mm as the largest diameter either proximal or distal to the lesion. Exclusion Criteria: The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours. There is any visual angiographic or ultrasound evidence of intraluminal thrombus thought to increase the risk of plaque fragmentation and distal embolization. There is total occlusion of the target carotid artery treatment site. The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having >95% stenosis where the true diameter of the distal vessel cannot be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm. The patient has any intracranial aneurysm (> 9 mm).

Sites / Locations

  • Cleveland Clinic

Outcomes

Primary Outcome Measures

The primary endpoint of this study is a 30-day composite of major adverse clinical events (MAE) including any death, myocardial infarction, or stroke.

Secondary Outcome Measures

Full Information

First Posted
September 30, 2005
Last Updated
July 19, 2007
Sponsor
Cordis Corporation
search

1. Study Identification

Unique Protocol Identification Number
NCT00231231
Brief Title
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
Official Title
Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2007
Overall Recruitment Status
Completed
Study Start Date
September 2004 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
November 2006 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
Cordis Corporation

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of this study is to assess the outcomes of stenting with distal protection in the treatment of obstructive carotid artery disease during peri-approval/initial commercialization in relation to the outcomes of the Sapphire Clinical Trial. The devices to be utilized are the Cordis PRECISE Nitinol Stent Systems and the Cordis ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Carotid Artery Disease

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
1500 (false)

8. Arms, Groups, and Interventions

Intervention Type
Device
Intervention Name(s)
-PRECISE Nitinol Stent System (5F, 5.5F and 6F)
Intervention Type
Device
Intervention Name(s)
ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)
Primary Outcome Measure Information:
Title
The primary endpoint of this study is a 30-day composite of major adverse clinical events (MAE) including any death, myocardial infarction, or stroke.
Time Frame
30 day

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: The patient must be > 18 years of age. The patient has a 50% stenosis (as determined by ultrasound or angiogram) of the common or internal carotid artery and is clinically symptomatic; i.e., within the previous 180 days has experienced symptoms in the ipsilateral carotid artery distribution, defined as: one or more TIAs, characterized by distinct focal neurologic dysfunction or monocular blindness with clearing of signs and symptoms within 24 hours, or one or more completed strokes (as defined by this protocol) with persistence of symptoms or signs for more than 24 hours (the most recent event is used as the qualifying event), except as excluded below, with stenosis >50%, (as determined by ultrasound or angiogram) of the common or internal carotid artery, OR The patient must have a >80% diameter stenosis (as determined by ultrasound or angiogram) of the internal or common carotid artery without neurological symptoms. To be entered into the study, the patient must have one or more of the following conditions: · congestive heart failure (class III/IV) and/or known severe left ventricular dysfunction LVEF < 30% open heart surgery within six weeks recent MI (>24 hours and <4 weeks) unstable angina (CCS class III/IV) synchronous severe cardiac and carotid disease requiring open heart surgery and carotid revascularization severe pulmonary disease to include any of the following: chronic oxygen therapy resting PO2 of 60 mmHg baseline hematocrit 50% FEV1 or DLCO 50% of normal. · contralateral carotid occlusion · contralateral laryngeal palsy · post-radiation treatment · previous CEA recurrent stenosis · high cervical ICA lesions · CCA lesions below the clavicle · severe tandem lesions abnormal stress test. 4. The qualifying ultrasound or angiogram was performed less than 30 days prior to study entry. · Stenosis >50%: PSV>130 cm/sec; EDV <135 cm/sec · Stenosis >80%: PSV>220 cm/sec; EDV <135 cm/sec · PSV ICA/PSV CCA ratio 4.0 5. The target vessel is in the native common or internal carotid artery. The arterial segment to be treated has a diameter between 4 mm and 9 mm as the largest diameter either proximal or distal to the lesion. Exclusion Criteria: The patient is experiencing an acute ischemic neurologic stroke or has experienced a stroke within the past 48 hours. There is any visual angiographic or ultrasound evidence of intraluminal thrombus thought to increase the risk of plaque fragmentation and distal embolization. There is total occlusion of the target carotid artery treatment site. The reference segment diameter (distal common carotid and internal carotid artery segment cephalic to the lesion) is less than 4mm or greater than 9mm. See Instructions For Use, for proper stent sizing. The exception to this would be with a lesion having >95% stenosis where the true diameter of the distal vessel cannot be determined such as the case with a string sign or distal vessel collapse. In this case the judgment of the interventionalist will prevail with the intention not to oversize the stent to the distal vessel by more than 2mm. The patient has any intracranial aneurysm (> 9 mm).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sidney A. Cohen, MD, PhD
Organizational Affiliation
Cordis Corporation
Official's Role
Study Director
Facility Information:
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States

12. IPD Sharing Statement

Citations:
PubMed Identifier
17630678
Citation
Katzen BT, Criado FJ, Ramee SR, Massop DW, Hopkins LN, Donohoe D, Cohen SA, Mauri L; CASES-PMS Investigators. Carotid artery stenting with emboli protection surveillance study: thirty-day results of the CASES-PMS study. Catheter Cardiovasc Interv. 2007 Aug 1;70(2):316-23. doi: 10.1002/ccd.21222.
Results Reference
result
PubMed Identifier
20620717
Citation
Schreiber TL, Strickman N, Davis T, Kumar V, Mishkel G, Foster M, Donohoe D, Britto S, Ansel G; CASES-PMS Investigators. Carotid artery stenting with emboli protection surveillance study: outcomes at 1 year. J Am Coll Cardiol. 2010 Jun 29;56(1):49-57. doi: 10.1016/j.jacc.2010.02.045.
Results Reference
derived

Learn more about this trial

Carotid Artery Stenting With Emboli Protection Surveillance-Post-Marketing Study (CASES-PMS)

We'll reach out to this number within 24 hrs